MSR1 and glioblastoma: It has been reported that primary tumors of patients with GBM, which have increased levels of M2-like TAMs (CD204+ cells), were responsible for a more-resistant pro-tumorigenic microenvironment and thus were associated with GBM aggressiveness, treatment resistance, and poor prognosis (110) (Figure 1).